• Tel:1-862-686-3631
  • Fax: 1-323-978-5598
Home > Products > Recombinant Proteins > Cynomolgus&Rhesus Proteins >

Recombinant Cynomolgus RANKL / OPGL / TNFSF11 Protein (Fc Tag) Online Inquiry

Cat#:RP-RANKL-01C
Product Name:Recombinant Cynomolgus RANKL / OPGL / TNFSF11 Protein (Fc Tag)
Synonym: CD254,hRANKL2,ODF,OPGL,OPTB2,RANKL,sOdf,TRANCE
Description: A DNA sequence encoding the cynomolgus RANKL/TNFSF11 (G7PW41) (Gly136-Asp317) was expressed with the Fc region of human IgG1 at the N-terminus. Recombinant cynomolgus RANKL protein was produced in Human cells. The RANKL cynomolgus recombinant protein was purified by our unique chromatographic techniques.
Source: Human Cells
Predicted N Terminal: Glu
Molecular Characterization: The recombinant cynomolgus RANKL/TNFSF11 comprises 442 amino acids and has a calculated molecular mass of 48.9 KDa. The apparent molecular mass of the protein is approximately 55 KDa in SDS-PAGE.
Purity: Greater than 85 % as determined by SDS-PAGE
Endotoxin: < 1.0 EU per μg of the cynomolgus RANKL protein as determined by the LAL method
Bioactivity: The bioactivity of RANKL protein was determined by measuring the ability of RANKL to induce TRAP activity in Raw 264.7 cells.
Formulation: Recombinant Cynomolgus RANKL protein was lyophilized from sterile PBS, pH 7.4
Stability: Recombinant Cynomolgus RANKL Proteins are stable for up to 1 year from date of receipt at -70℃
Storage: Lyophilized recombinant cynomolgus RANKL protein is stable at 4-8℃ for 2-4 weeks. Upon reconstitution, Recombinant cynomolgus RANKL protein should be stored at 4°C between 2-7 days and for future use below -20°C. Avoid freeze-thaw cycles.
References: 1. Nakashima T, et al. (2003) RANKL and RANK as novel therapeutic targets for arthritis. Curr Opin Rheumatol. 15(3): 280-7. 2.Leibbrandt A, et al. (2008) RANK/RANKL: regulators of immune responses and bone physiology. Ann N Y Acad Sci. 1143: 123-50.

Online Inquiry

refresh